GSK has made a $70 million down payment to expand the partnership, with an undisclosed minimum financial commitment over three years that can be extended to five if desired. Image.

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya.

View GSK plc Sponsored ADR GSK stock quote prices, financial information, real-time forecasts, and company news from CNN.

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio ...

View the latest Koppers Holdings Inc. (KOP) stock price, news, historical charts, analyst ratings and financial information from WSJ.